EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

Jun 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-06-21

Reporting Person: Peterson Kristine (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-21	Employee Stock Option (right to buy)	$1.95	A	26667	Acquired	2028-06-21	Common Stock (26667)	Direct
2018-06-21	Deferred Stock Units	$	A	6667	Acquired		Common Stock (6667)	Direct
2018-06-21	Employee Stock Option (right to buy)	$1.95	A	40000	Acquired	2028-06-21	Common Stock (40000)	Direct

Footnotes

F1: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company").

F2: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder.

F3: The option becomes exercisable in two equal annual installments beginning on June 21, 2019.